news
COVID-19 mRNA vaccine technology transfer hub to be set up in South Africa
A South African consortium will be the first to establish a COVID-19 mRNA vaccine technology transfer hub to scale up vaccine production and access.
List view / Grid view
Coronavirus
news
Real-world evidence confirms Veklury® reduces COVID-19 mortality
New real-world analyses demonstrate Veklury® (remdesivir) reduces mortality and increases likelihood of discharge in hospitalised COVID-19 patients.
news
COVID-19 vaccines highly effective against hospitalisation by Delta variant
21 June 2021 | By
An analysis shows Comirnaty® and the COVID-19 Vaccine AstraZeneca are both over 90 percent effective in preventing hospitalisation from the Delta variant.
news
Targeted drug delivery enabled by genetically engineered nanoparticles
In a pre-clinical study, researchers were able to genetically engineer cell membrane-coated nanoparticles to deliver dexamethasone directly to the inflamed lungs of mice.
news
Global clinical trials market to value $77 billion by 2026
Market analysts suggest COVID-19 and the rising prevalence of chronic disease will both contribute to growth in the global clinical trials market.
article
COVID-19 antibody therapeutics – where are they now?
In this article, EPR’s Hannah Balfour explores the current usage of monoclonal antibody therapies for COVID-19, with commentary from Professor Adrian Streinu-Cercel of the Carol Davila University of Medicine and Pharmacy.
![MBE Medals [Credit: HCSA (Health Care Supply Association)].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/MBE-300x278.png)
![MBE Medals [Credit: HCSA (Health Care Supply Association)].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/MBE.png)
news
MBE awarded to NICE’s Interventional Procedures Advisory Committee chairman
Professor Tom Clutton-Brock was awarded an MBE for his work in approving novel ventilators for the UK’s National Health Service during the COVID-19 pandemic.
news
Antibody cocktail improves survival in seronegative hospitalised COVID-19 patients
Phase III data shows REGEN-COV™ (casirivimab and imdevimab) reduced risk of death by 20 percent in hospitalised COVID-19 patients lacking an immune response to SARS-CoV-2.
news
NVX-CoV2373 vaccine 90 percent effective in preventing symptomatic COVID-19
US trial results show NVX-CoV2373 was safe and effective in preventing symptomatic COVID-19, including in high-risk populations.
news
Co-administration of flu and COVID-19 vaccines safe and effective
A trial comparing co-administration of influenza and COVID-19 vaccines to COVID-19 vaccine dosing alone found little effect on vaccine efficacy.
news
Health Canada to modernise its clinical trial regulations
Health Canada has proposed a single regulatory framework for clinical trials for all health products that will support innovation and streamline drug and medical device development.
news
G7 to share 870 million doses of COVID-19 vaccine with poorest countries
Global leaders at the G7 summit pledged 870 million COVID-19 vaccine doses, with half to be delivered by the end of 2021, to COVAX for distribution among low- and middle-income countries.
news
Pharmacovigilance Risk Assessment Committee meeting highlights, June 2021
The European Medicines Agency (EMA)’s drug safety committee (PRAC) concluded three safety signal reviews, two for COVID-19 interventions, at its June meeting.
news
Janssen COVID-19 Vaccine – one regulator blocks use, another promotes it
EU recommends that batches of Janssen COVID-19 Vaccine not be released for use due to a cross contamination report, while the FDA authorises use of drug substance from the facility where the contamination occurred.
news
Comirnaty® COVID-19 vaccine protects against multiple viral variants
Laboratory study shows the blood sera of people vaccinated against COVID-19 with Comirnaty® can neutralise at least six viral variants including three variants of concern.
